JP2021512120A5 - - Google Patents

Info

Publication number
JP2021512120A5
JP2021512120A5 JP2020541922A JP2020541922A JP2021512120A5 JP 2021512120 A5 JP2021512120 A5 JP 2021512120A5 JP 2020541922 A JP2020541922 A JP 2020541922A JP 2020541922 A JP2020541922 A JP 2020541922A JP 2021512120 A5 JP2021512120 A5 JP 2021512120A5
Authority
JP
Japan
Prior art keywords
vsig3
antibody
chain variable
variable region
clones
Prior art date
Application number
JP2020541922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512120A (ja
JPWO2019152810A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016301 external-priority patent/WO2019152810A1/en
Publication of JP2021512120A publication Critical patent/JP2021512120A/ja
Publication of JP2021512120A5 publication Critical patent/JP2021512120A5/ja
Publication of JPWO2019152810A5 publication Critical patent/JPWO2019152810A5/ja
Pending legal-status Critical Current

Links

JP2020541922A 2018-02-02 2019-02-01 Vistaとvsig3との相互作用を調節する化合物ならびにその製造および使用方法 Pending JP2021512120A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862625594P 2018-02-02 2018-02-02
US62/625,594 2018-02-02
US201862627478P 2018-02-07 2018-02-07
US62/627,478 2018-02-07
PCT/US2019/016301 WO2019152810A1 (en) 2018-02-02 2019-02-01 Compounds that modulate the interaction of vista and vsig3 and methods of making and using

Publications (3)

Publication Number Publication Date
JP2021512120A JP2021512120A (ja) 2021-05-13
JP2021512120A5 true JP2021512120A5 (https=) 2022-02-09
JPWO2019152810A5 JPWO2019152810A5 (https=) 2022-02-09

Family

ID=65444360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541922A Pending JP2021512120A (ja) 2018-02-02 2019-02-01 Vistaとvsig3との相互作用を調節する化合物ならびにその製造および使用方法

Country Status (5)

Country Link
US (1) US11787857B2 (https=)
EP (1) EP3746477A1 (https=)
JP (1) JP2021512120A (https=)
CN (1) CN111868082A (https=)
WO (1) WO2019152810A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494141A4 (en) 2016-08-03 2020-04-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
CA3146023A1 (en) 2019-07-05 2021-01-14 Iomx Therapeutics Ag Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
EP4175668A1 (en) 2020-07-06 2023-05-10 iOmx Therapeutics AG Antibodies binding igv of igsf11 (vsig3) and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5149491A (en) 1990-07-10 1992-09-22 General Electric Company Seed and blanket fuel arrangement for dual-phase nuclear reactors
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6982323B1 (en) 1997-12-23 2006-01-03 Alexion Pharmaceuticals, Inc. Chimeric proteins for diagnosis and treatment of diabetes
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2001000814A2 (en) 1999-06-25 2001-01-04 Universität Zürich Hetero-associating coiled-coil peptides and screenign method therefor
WO2001001137A1 (en) 1999-06-30 2001-01-04 Children's Medical Center Corporation Fusion protein and uses thereof
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
WO2002064834A1 (en) 2001-01-04 2002-08-22 Myriad Genetics, Inc. Novel two-hybrid system and use thereof
EP1421203A4 (en) 2001-05-17 2005-06-01 Diversa Corp NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
KR101077177B1 (ko) 2002-06-06 2011-10-27 온코세라피 사이언스 가부시키가이샤 사람 결장암에 관계하는 유전자 및 폴리펩티드
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
DK1812031T3 (en) 2004-11-01 2015-09-14 Univ California Compositions and methods for the modification of biomolecules
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US20180237525A9 (en) 2010-03-26 2018-08-23 Randolph J. Noelle VISTA Agonist and Methods of Use
MX2014014951A (es) 2012-06-06 2015-03-13 Oncomed Pharm Inc Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
DK3421486T5 (da) 2012-06-22 2024-09-16 The Trustees Of Darthmouth College Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのvista調節剤
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
WO2016020880A2 (en) * 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト,インコーポレーテッド 推定上のvista受容体としてのvsig8の同定と、vista/vsig8調節剤を産生するためのその使用
EP3494141A4 (en) 2016-08-03 2020-04-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using

Similar Documents

Publication Publication Date Title
CN109651507B (zh) 一种激动型4-1bb单克隆抗体
JP7600328B2 (ja) PD-1とTGF-betaを標的とした四価二重特異性抗体、その製造方法および用途
WO2022166940A1 (en) Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors
JP2023134705A5 (https=)
JP2018502050A5 (https=)
JP2021512120A5 (https=)
JP2022104966A (ja) a-syn/IGF1Rに対する二重特異抗体およびその用途
EP3768721A1 (en) Novel anti-ctla-4 antibody polypeptide
CN118984839B (zh) 一种抗ccr8抗体或其抗原结合片段
US20220340677A1 (en) Split intein and preparation method for recombinant polypeptide using the same
CN115605511A (zh) 抗tigit的抗体、其制备方法和应用
CN113166269B (zh) 对抗检查点分子的多特异性结合构建体及其用途
KR20200013233A (ko) 신규 항 cd3 항체
CN109721656B (zh) 靶向rankl的治疗性抗体
CN114790242A (zh) 一种结合人pd-l1的抗体
JP2022500455A5 (https=)
CN113677701B (zh) 产生亲合结合多特异性抗体的方法
WO2023131328A9 (zh) 一种抗体及其用途
JP2021506310A5 (https=)
CN118251419A (zh) 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
JPWO2022042488A5 (https=)
JP7652705B2 (ja) Btn2に対する特異性を有する抗体及びその使用
CN115746144B (zh) 抗tigit-pd1双特异性抗体及其应用
CN114957468A (zh) 一种抗Siglec15抗体及其用途
KR102314157B1 (ko) TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법